PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects

Neuropharmacology

Volumn 39, Issue 7, 2000, Pages 1211-1221

  Corbin, A E ^a   Meltzer, L T ^a   Ninteman, F W ^a   Wiley, J N ^a   Christoffersen, C L ^a   Wustrow, D J ^a   Wise, L D ^a   Pugsley, T A ^a   Heffner, T G ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT(1A) agonist; Antipsychotic; Avoidance responding; Extrapyramidal dysfunction; Locomotor activity; Partial dopamine agonist

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 2 [4 [2 (4 PHENYL 1 PIPERAZINYL)ETHYL]CYCLOHEXYLAMINO]PYRIMIDINE; AMPHETAMINE; APOMORPHINE; CHLORDIAZEPOXIDE; DEXAMPHETAMINE; GEPIRONE; HALOPERIDOL; IMIPRAMINE; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; NEUROLEPTIC AGENT; PRECLAMOL; QUIPAZINE; RISPERIDONE; ROXINDOLE; TALIPEXOLE; TERGURIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; LOCOMOTION; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STEREOTYPY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; CATALEPSY; CEBUS; CONFLICT (PSYCHOLOGY); DOPAMINE AGONISTS; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; PYRIMIDINES; RATS; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SAIMIRI; SEROTONIN AGONISTS;

EID: 0034117854     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00214-2     Document Type: Article

References (56)

1. Abi-Dargham A., Laruelle M., Charney D., Krystal J. Serotonin and schizophrenia: a review. Drugs of Today. 32:1996;171-185.
2. 1A partial agonist PD 158771, a potential antipsychotic, on monoamine synthesis and release in rats. Society for Neuroscience Abstracts. 22:1996;1188.
3. 1A agonistactions (see companion paper). I. Neurochemical Effects. Neuropharmacology. (in press).
4. Arnt J., Hyttel J. Dopamine D-2 agonists with high and low efficacies: differentiation by behavioral techniques. Journal of Neural Transmission. 80:1990;33-50.
5. Baldessarini R.J., Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annual Review of Neurosciences. 3:1980;23-41.
6. Bouthenet M.-L., Souil E., Martres M.-P., Sokoloff P., Giros B., Schwartz J.-C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Research. 564:1991;203-219.
7. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. American Journal of Psychiatry. 135:1978;164-173.
8. Carpenter W.T. Jr. Serotonin-dopamine antagonists and treatment of negative symptoms. Journal of Clinical Psychopharmacology. 15:1995;30S-35S.
9. Casey D.E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacology Bulletin. 27:1991;47-50.
10. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology. 112:1993;S55-S59.
11. Christoffersen C.L., Meltzer L.T. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology. 18:1998;1-4.
12. Clark D., Furmidge L.J., Petry N., Tong Z.-Y., Ericsson M., Johnson D. Behavioural profile of partial D2 dopamine receptor agonists 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology. 105:1991;381-392.
13. Curtis V.A., Kerwin R. Evidence for a role for serotonin in schizophrenia. Implications for pharmacological management. Journal of Serotonin Research. 1:1995;1-7.
14. Daly S.A., Waddington J.L. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other 'D2-like' agonists. Neuropharmacology. 32:1993;509-510.
15. Damsma G., Bottema T., Westerink B.H.C., Tepper P., Dijkstra D., Pugsley T.A., Mackenzie R.G., Heffner T.G., Wikström H. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. European Journal of Pharmacology. 249:1993;R9-R10.
16. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
17. Gerlach J., Peacock L. New antipsychotics: the present status. International Clinical Psychopharmacology. 10:1995;39-48.
18. Heffner T.G., Downs D.A., Meltzer L.T., Wiley J.N., Williams A.E. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects. Journal of Pharmacology and Experimental Therapeutics. 251:1989;105-112.
19. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry. 45:1988;789-796.
20. Landwehrmeyer B., Mengod G., Palacios J.M. Dopamine D3 receptor mRNA and binding sites in human brain. Molecular Brain Research. 18:1993;187-192.
21. Lévesque D., Diaz J., Pilon C., Martres M.-P., Giros B., Souil E., Schott D., Morgat J.-L., Schwartz J.-C., Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proceedings of the National Academy of Sciences USA. 89:1992;8155-8159.
22. Lucki I., Singh A., Kreiss D.S. Antidepressant-like behavioral effects of serotonin receptor agonists. Neuroscience Biobehavior Reviews. 18:1994;85-95.
23. McMillen B.A., Scott S.M., Davanzo E.A. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. Journal Pharm. Pharmacol. 40(12):1988;885-887.
24. Meller E., Bohmaker K., Goldstein M., Basham D.A. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. European Journal of Pharmacology. 249:1993;R5-R6.
25. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin. 2(1):1976;19-76.
26. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
27. Meltzer H.Y. The role of serotonin receptor antagonism: the action of atypical antipsychotic drugs. Takada A., Curzon G. Serotonin in the Central Nervous System and Periphery. 1995;169-174 Elsevier Science, Amsterdam.
28. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clinical Neuroscience. 3:1995;64-75.
29. Meltzer L.T., Christoffersen C.L., Corbin A.E., Ninteman F.W., Serpa K.A., Wiley J.N., Wise L.D., Heffner T.G. CI 1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. Journal of Pharmacology and Experimental Therapeutics. 274:1995;912-920.
30. Moore N.A., Tupper D.E., Hotten T.M. Olanzapine. Drugs of the Future. 19:1994;114-117.
31. Naber D., Gaussares C., Moeglen J.M., Tremmel L., Bailey P.E. Efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia. Meltzer H.Y. Novel Antipsychotic Drugs. 1992;99-107 Raven Press, New York.
32. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement of haloperidol-induced catalepsy. Journal of Pharmacology and Experimental Therapeutics. 265(1):1993;207-217.
33. 1A receptors. Neuropharmacology. 35(1):1996;119-121.
34. Ninteman F.W., Johnston D.J., Wiley J.N., Corbin A.E., Heffner T.G. Improved sensitivity of a water wheel automated behavioral despair test using Wistar-Kyoto rats. Society for Neuroscience Abstracts. 21:1995;1132.
35. 1A partial agonist, PD 158771: a potential antipsychotic. Society of Neuroscience Abstracts. 22:1996;1187.
36. 2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles. Journal of Medical Chemistry. 35:1992;4813-4822.
37. 1A/dopamine agonist. Journal of Pharmacology and Experimental Therapeutics. 268:1994;1304-1310.
38. Pugsley T.A., Davis M.D., Akunne H.C., Mackenzie R.G., Shih Y.-H., Damsma G., Wikström H., Whetzel S.Z., Cooke L.W., Georgic L.M., DeMattos S.B., Corbin A.E., Wise L.D., Dijkstra D., Heffner T.G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Journal of Pharmacology and Experimental Therapeutics. 275:1995;1355-1366.
39. Pugsley T.A., Davis M.D., Akunne H.C., Cooke L.W., Whetzel S.Z., Mackenzie R.G., Shih Y.-H., Van Leeuwen D.H., DeMattos S.B., Georgic L.M., Caprathe B.W., Wright J.L., Jaen J.C., Wise L.D., Heffner T.G. CI-1007, a dopamine autoreceptor agonist and potential antipsychotic agent. I. Neurochemical effects. Journal of Pharmacology and Experimental Therapeutics. 274:1995;898-911.
40. 1A receptor activation. European Journal of Pharmacology. 338(2):1997;R3-R5.
41. Roth R.H. Dopamine autoreceptors: pharmacology, function and comparison with postsynaptic dopamine receptors. Communications in Psychopharmacology. 3:1979;429-445.
42. Roth R.H. CNS dopamine autoreceptors: distribution, pharmacology and function. Annals of the New York Academy of Sciences. 430:1984;27-53.
43. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., McLean S., Guaanowsky V., Howard H.R., Lowe I., Heym J. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology and Experimental Therapeutics. 275:1995;101-113.
44. Sokoloff P., Giros B., Martres M.-P., Bouthenet N.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
45. Svensson K., Ekman A., Piercey M.F., Hoffman W.E., Lum J.T., Carlsson A. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn-Schmiedeberg's Archives of Pharmacology. 344:1991;263-274.
46. Svensson K., Carlsson A., Waters N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. Journal of Neural Transmission. 98:1994;71-74.
47. Tallarida R.J., Murray R.B. Pharm/PCS version 4.2, a Pharmacologic Calculation System Based on Manual of Pharmacologic Calculations with Computer Programs. 1986;Springer-Verlag, New York.
48. Tang L., Todd R.D., O'Malley K.L. Dopamine D2 and D3 receptors inhibit dopamine release. Journal of Pharmacology and Experimental Therapeutics. 270:1994;475-479.
49. Taylor D.P. Serotonin agents in anxiety. Annals of the New York Academy of Sciences. 600:1990;545-557.
50. van Kammen D.P., Peters J., van Kammen W.B., Nugent A., Goetz K.L., Yao J., Linnoila M. Elevated CSF NE and relapse in schizophrenia. Biological Psychiatry. 26:1989;178-188.
51. 1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacology, Biochemistry and Behavior. 47(3):1994;509-513.
52. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. Journal of Neural Transmission. 94:1993;11-19.
53. Wiedemann K., Krieg J.C., Loycke A., Hosboer F. Novel dopamine agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia. Meltzer H. Novel Antipsychotic Drugs. 1992;91-98 Raven Press, New York.
54. Wustrow D.J., Wise L.D. Progress in developing dopamine D3 ligands as potential antipsychotic agents. Current Pharmaceutical Design. 3:1997;391-404.
55. Wustrow D., Belliotti T., Glase S., Ross-Kesten S., Johnson D., Colbry N., Rubin R., Blackburn A., Akunne H., Corbin A., Davis M.D., Georgic L., Whetzel S., Zoski K., Heffner T., Pugsley T., Wise L. Aminopyridines with high affinity for both serotonin and dopamine receptors. Journal of Medical Chemistry. 41(5):1998;760-771.
56. 1A partial agonist PD 158771, a potential antipsychotic. Society for Neuroscience Abstracts. 22:1996;1188.